Paragon 28 (FNA) Stock Forecast & Price Target

$6.67

+0.13 (+1.99%)

(As of 09/30/2024 ET)

Paragon 28 - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 4 Analyst Ratings

Sell
0

Hold
0

Buy
4

Based on 4 Wall Street analysts who have issued ratings for Paragon 28 in the last 12 months, the stock has a consensus rating of "Buy." Out of the 4 analysts, 4 have given a buy rating for FNA.

Consensus Price Target

$15.25
128.64% Upside

According to the 4 analysts' twelve-month price targets for Paragon 28, the average price target is $15.25. The highest price target for FNA is $20.00, while the lowest price target for FNA is $11.00. The average price target represents a forecasted upside of 128.64% from the current price of $6.67.

Get the Latest News and Ratings for FNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Paragon 28 and its competitors.

FNA Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$15.25	$15.25	$16.75	$28.20
Forecasted Upside	128.64% Upside	83.29% Upside	156.90% Upside	133.83% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Shedding light on a dark secret (Ad)

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.

Watch this new documentary and you’ll discover what Elon knows,

FNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

FNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Paragon 28 Stock vs. The Competition

Type	Paragon 28	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.78	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	128.64% Upside	822.76% Upside	6.15% Upside
News Sentiment Rating	Neutral News See Recent FNA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/9/2024	Piper Sandler 2 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$15.00 ➝ $12.00	+69.01%
8/9/2024	Needham & Company LLC 2 of 5 stars		Lower Target	Buy ➝ Buy	$14.00 ➝ $11.00	+32.21%
5/9/2024	JMP Securities 2 of 5 stars		Lower Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $20.00	+144.20%
4/5/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$18.00	+80.00%
9/29/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Vazquez Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
12/14/2022	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Chatterji Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$32.00	+57.17%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:24 AM ET.

FNA Forecast - Frequently Asked Questions

: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Paragon 28 is $15.25, with a high forecast of $20.00 and a low forecast of $11.00.
: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Paragon 28 in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FNA shares.
: According to analysts, Paragon 28's stock has a predicted upside of 128.64% based on their 12-month stock forecasts.
: Paragon 28 has been rated by research analysts at Needham & Company LLC, and Piper Sandler in the past 90 days.
: Analysts like Paragon 28 more than other "medical" companies. The consensus rating for Paragon 28 is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how FNA compares to other companies.